Skip to main content
Premium Trial:

Request an Annual Quote

GenPath Women's Health ClariTest

GenPath Women's Health, a business unit of BioReference Laboratories, is offering ClariTest, a noninvasive prenatal test that will be initially performed at Illumina. The test leverages massively parallel sequencing technology to screen for trisomies 13, 18, and 21, and sex chromosome abnormalities. It also offers the option to screen for five microdeletions, including 22q11.2, or DiGeorge syndrome. The company said that it will ultimately develop and validate its own laboratory-developed NIPT using Illumina technology.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.